• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗不耐受局部治疗的青光眼患者的眼表疾病对眼内压的影响:10 例报告。

Influence of Treating Ocular Surface Disease on Intraocular Pressure in Glaucoma Patients Intolerant to Their Topical Treatments: A Report of 10 Cases.

机构信息

Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, DHU Sight Restore.

CHNO des Quinze-Vingts, DHU Sight Restore, INSERM-DHOS CIC.

出版信息

J Glaucoma. 2018 Dec;27(12):1105-1111. doi: 10.1097/IJG.0000000000001041.

DOI:10.1097/IJG.0000000000001041
PMID:30489502
Abstract

PURPOSE

The purpose of this study was to evaluate the effect of treating ocular surface disease (OSD) in patients with medically uncontrolled primary open-angle glaucoma (POAG) associated with OSD.

METHODS

We compiled a retrospective observational case series of 10 patients with POAG that remained uncontrolled with topical treatments and who were referred for filtering glaucoma surgery. All patients underwent a complete assessment of their glaucoma and ocular surface for both eyes. The main treatments were change of topical antiglaucoma medications to preservative-free equivalents, removal of allergenic treatments or those identified as causing side effects, switch to another therapeutic class with the same efficacy but with a better safety profile and treatment of OSD.

RESULTS

After a minimum follow-up of 6 months, we observed improved ocular surface in all patients, associated with an intraocular pressure (IOP) decrease or stabilization even if some antiglaucoma medications were removed. The mean IOP significantly decreased from 23.75±9.98 mm Hg to 15.15±4.75 mm Hg (-36.2%; P=0.0001). The mean number of IOP-lowering medications was 3.7±1.06 at presentation and 2.8±0.63 after treatment (P=0.01). The Oxford score also decreased from a mean 1.7±0.67 to 0.4±0.51 (-76.5%; P<0.001). For 2 patients, IOP was not sufficiently reduced after treatment and they finally underwent filtering surgery.

CONCLUSIONS

The prevalence of OSD in POAG patients is very high, particularly in patients with uncontrolled glaucoma with multiple topical medications. Careful management of the ocular surface associated with a reduction of the toxicity of eyedrops may result in improvement of ocular surface health and better IOP control.

摘要

目的

本研究旨在评估治疗伴有眼表疾病(OSD)的药物控制不良原发性开角型青光眼(POAG)患者的眼表疾病的效果。

方法

我们汇编了 10 例 POAG 患者的回顾性观察性病例系列,这些患者因眼部表面疾病而无法用局部治疗控制,因此被转诊接受滤过性青光眼手术。所有患者均对双眼的青光眼和眼表进行了全面评估。主要治疗方法包括:将局部抗青光眼药物更换为不含防腐剂的等效药物,停用过敏原治疗或已确定有副作用的治疗方法,改用疗效相同但安全性更好的另一类治疗药物,并治疗眼表疾病。

结果

在至少 6 个月的随访后,我们观察到所有患者的眼表均得到改善,眼压(IOP)降低或稳定,即使一些抗青光眼药物被停用。平均 IOP 从 23.75±9.98mmHg 显著降低至 15.15±4.75mmHg(下降 36.2%;P=0.0001)。就诊时平均使用 3.7±1.06 种降眼压药物,治疗后降至 2.8±0.63 种(P=0.01)。牛津评分也从平均 1.7±0.67 降至 0.4±0.51(下降 76.5%;P<0.001)。对于 2 例患者,治疗后眼压仍未充分降低,最终接受了滤过性手术。

结论

POAG 患者的 OSD 患病率非常高,特别是在伴有多种局部药物治疗的未控制青光眼患者中。仔细管理眼表并减少滴眼剂的毒性可能会改善眼表健康状况并更好地控制眼压。

相似文献

1
Influence of Treating Ocular Surface Disease on Intraocular Pressure in Glaucoma Patients Intolerant to Their Topical Treatments: A Report of 10 Cases.治疗不耐受局部治疗的青光眼患者的眼表疾病对眼内压的影响:10 例报告。
J Glaucoma. 2018 Dec;27(12):1105-1111. doi: 10.1097/IJG.0000000000001041.
2
Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control.眼表疾病加重青光眼:改善眼表可优化眼压控制。
J Glaucoma. 2014 Jan;23(1):56-60. doi: 10.1097/IJG.0b013e318264cd68.
3
Relation between office intraocular pressure and 24-hour intraocular pressure in patients with primary open-angle glaucoma treated with a combination of topical antiglaucoma eye drops.使用局部抗青光眼滴眼液联合治疗的原发性开角型青光眼患者的诊室眼压与24小时眼压之间的关系
J Glaucoma. 2007 Mar;16(2):201-4. doi: 10.1097/IJG.0b013e31802ff85f.
4
Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications.使用局部降眼压药物的青光眼患者的眼表不适患病率。
Cornea. 2010 Jun;29(6):618-21. doi: 10.1097/ICO.0b013e3181c325b2.
5
Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.一项临床审计,考察不含苯扎氯铵的抗青光眼药物对有眼表疾病症状患者的影响。
Clin Exp Ophthalmol. 2015 Apr;43(3):214-20. doi: 10.1111/ceo.12431. Epub 2014 Oct 2.
6
Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.青光眼局部治疗患者的眼表疾病
Eur J Ophthalmol. 2017 Nov 8;27(6):694-704. doi: 10.5301/ejo.5000977.
7
Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study.局部青光眼治疗与眼表疾病:一项前瞻性对照队列研究。
Can J Ophthalmol. 2015 Apr;50(2):132-6. doi: 10.1016/j.jcjo.2014.11.006.
8
Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.0.1%无防腐剂噻吗洛尔凝胶在初治开角型青光眼和高眼压症患者以及对其他降压药物不耐受患者中的疗效和安全性。
J Fr Ophtalmol. 2018 Dec;41(10):945-954. doi: 10.1016/j.jfo.2018.04.012. Epub 2018 Nov 23.
9
Intraocular pressure changes following topical ocular hypotensive medications washout.局部眼降压药物冲洗后眼压变化。
Br J Ophthalmol. 2021 Feb;105(2):205-209. doi: 10.1136/bjophthalmol-2019-315778. Epub 2020 Apr 10.
10
Long term effect of phacoemulsification on intraocular pressure in patients with medically controlled primary open-angle glaucoma.超声乳化白内障吸除术对药物控制的原发性开角型青光眼患者眼压的长期影响。
BMC Ophthalmol. 2019 Jul 12;19(1):149. doi: 10.1186/s12886-019-1157-3.

引用本文的文献

1
Association Between Preserved Glaucoma Eye Drops Exposure and Glaucoma Surgery Occurrence: A Nationwide 10-Year Outcome Study.青光眼滴眼液持续使用与青光眼手术发生率之间的关联:一项全国性10年结局研究。
Ophthalmol Ther. 2025 Aug 22. doi: 10.1007/s40123-025-01203-1.
2
A phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension.一项比较无防腐剂拉坦前列素滴眼液乳剂与含防腐剂拉坦前列素治疗开角型青光眼或高眼压症的III期研究。
Eye (Lond). 2025 Jun;39(8):1599-1607. doi: 10.1038/s41433-025-03646-z. Epub 2025 Feb 25.
3
Evidence in Practice: A Review of Real-Life Studies and Clinical Experience with the Preservative-Free Tafluprost (0.0015%) and Timolol (0.5%) Fixed-Dose Combination.
实践中的证据:关于无防腐剂他氟前列素(0.0015%)与噻吗洛尔(0.5%)固定剂量组合的真实研究及临床经验综述
Clin Ophthalmol. 2024 Nov 8;18:3185-3196. doi: 10.2147/OPTH.S479852. eCollection 2024.
4
Response predictors of a topical corticosteroid-based regimen for dry eyes: A real-life study.基于局部用皮质类固醇疗法治疗干眼症的反应预测因素:一项真实世界研究。
Acta Ophthalmol. 2025 Feb;103(1):93-98. doi: 10.1111/aos.16758. Epub 2024 Sep 30.
5
Real-Life Study on the Efficacy and Tolerance of a Preservative-Free Surfactant-Free Latanoprost Eye Drop in Patients with Glaucoma.不含防腐剂和表面活性剂的拉坦前列素滴眼液治疗青光眼患者疗效及耐受性的真实世界研究
Ophthalmol Ther. 2024 Oct;13(10):2661-2677. doi: 10.1007/s40123-024-01013-x. Epub 2024 Aug 12.
6
Glaucoma and ocular surface.青光眼与眼表
Indian J Ophthalmol. 2024 Mar 1;72(3):305-306. doi: 10.4103/IJO.IJO_376_24. Epub 2024 Feb 28.
7
Glaucoma and Dry Eye Disease: Opportunity to Assess and Treat.青光眼与干眼病:评估与治疗的契机。
Clin Ophthalmol. 2023 Oct 17;17:3063-3076. doi: 10.2147/OPTH.S420932. eCollection 2023.
8
Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease-a randomized controlled trial.从含防腐剂的环孢素 0.1%到不含防腐剂的环孢素 0.1%增强型三联青光眼治疗方案的转换:对眼表疾病的影响——一项随机对照试验。
Eye (Lond). 2023 Dec;37(17):3666-3674. doi: 10.1038/s41433-023-02578-w. Epub 2023 May 23.
9
Use of a Cationic Emulsion of Latanoprost to Treat Glaucoma Patients with Ocular Surface Disease: A Preclinical Review.使用拉坦前列素阳离子乳剂治疗伴有眼表疾病的青光眼患者:临床前评价。
J Ocul Pharmacol Ther. 2023 May;39(4):240-251. doi: 10.1089/jop.2022.0155. Epub 2023 Apr 4.
10
Prevalence of Ocular Surface Disease and Associated Risk Factors in Glaucoma Patients: A Survey Study of Ophthalmologists.青光眼患者的眼表疾病患病率及相关危险因素:眼科医生的调查研究。
Turk J Ophthalmol. 2022 Oct 28;52(5):302-308. doi: 10.4274/tjo.galenos.2021.20726.